专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20040009958A1 Methods for preparation and use of 1alpha,24(S)-dihydroxyvitamin D2 审中-公开
标题翻译：制备和使用1α，24（S） - 二羟基维生素D2的方法
公开(公告)号：US20040009958A1
公开(公告)日：2004-01-15
申请号：US10390953
申请日：2003-03-18
申请人： Bone Care International, Inc.
发明人： Charles W. Bishop , Joyce C. Knutson , Stephen Strugnell , Richard B. Mazess
IPC分类号： A61K031/7072 , A61K031/704 , A61K031/59 , A61K031/525 , A61K031/337 , A61K031/28
CPC分类号： A61K31/047 , A61K31/59 , A61K31/592 , A61K45/06 , C07C401/00 , C07J9/00 , C07J71/0042 , A61K2300/00
摘要： A method of inhibiting the hyperproliferation of malignant or neoplastic cells, comprising treating the cells with an antiproliferative amount of 1null,24(S)-dihydroxyvitamin D2. The method also includes the co-administration of cyotoxic agents with the 1null,24(S)-dihydroxyvitamin D2.
摘要翻译：一种抑制恶性或肿瘤细胞过度增殖的方法，包括用抗增生剂量的1α，24（S） - 二羟基维生素D 2处理细胞。该方法还包括联合给予1α，24（S） - 二羟基维生素D2的细胞毒性试剂。

62. 发明申请

US20040006007A1 Methods and compositions for treating hepatitis C virus using 4'-modified nucleosides 有权
标题翻译：使用4'-修饰核苷治疗丙型肝炎病毒的方法和组合物
公开(公告)号：US20040006007A1
公开(公告)日：2004-01-08
申请号：US10261244
申请日：2002-09-30
发明人： Gilles Gosselin , Jean-Louis Imbach , Jean-Pierre Sommadossi
IPC分类号： A61K038/14 , A61K031/7076 , A61K031/7072 , C07K009/00 , C07J001/00 , C07H019/067 , C07H019/073
CPC分类号： C07H19/06 , C07H19/056 , C07H19/16 , C07J1/00 , C07K9/00 , Y10S514/894
摘要： A compound, method and composition for treating a host infected with a hepatitis C viral comprising administering an effective hepatitis C treatment amount of a described 4null-disubstituted nucleoside or a pharmaceutically acceptable salt or prodrug thereof, is provided.
摘要翻译：提供用于治疗感染丙型肝炎病毒的宿主的化合物，方法和组合物，包括施用有效丙型肝炎治疗量的所述4'-二取代核苷或其药学上可接受的盐或前药。

63. 发明申请

US20040002476A1 Modified fluorinated nucleoside analogues 审中-公开
标题翻译：改性氟化核苷类似物
公开(公告)号：US20040002476A1
公开(公告)日：2004-01-01
申请号：US10366144
申请日：2003-02-13
发明人： Lieven J. Stuyver , Junxing Shi , Kyoichi A. Watanabe
IPC分类号： A61K031/7076 , A61K031/7072 , A61K031/522 , A61K031/513 , C07H019/073 , C07H019/06 , C07H019/067 , C07D473/14 , C07D45/02
CPC分类号： C07H19/06 , C07H19/16
摘要： The invention is a compound, composition, use for and a method of treating Flaviviridae (Hepacivirus, Flavirius, Pestivirus) infections, including BVDV and HCV, or abnormal cellular proliferation, including malignant tumors, in a host including animals, and especially humans, using a null-D or null-L nucleoside of general formula (I)-(XX), or their pharmaceutically acceptable salt or prodrug thereof.
摘要翻译：本发明是一种用于治疗包括BVDV和HCV在内的黄病毒科（Hepacivirus，Flavirius，Pestivirus）感染或包括恶性肿瘤在内的异常细胞增殖的化合物，组合物，用途和方法，包括动物，特别是人，使用通式（I） - （XX）的β-D或β-L核苷或其药学上可接受的盐或前药。

64. 发明申请

US20030225029A1 Dosing regimen for gemcitabine HCV therapy 审中-公开
标题翻译：吉西他滨HCV治疗的给药方案
公开(公告)号：US20030225029A1
公开(公告)日：2003-12-04
申请号：US10367388
申请日：2003-02-14
发明人： Lieven J. Stuyver
IPC分类号： A61K031/7072 , A61K031/513
CPC分类号： C07H19/06 , C07H19/16
摘要： A dosage regiment for the treatment of a Flaviviridae infection, including a hepatitis C viral infection, that includes administering gemcitabine (or its salt, prodrug or derivative, as described herein) in a dosage range of approximately 50 mg/m2 to about 1300 mg/m2 per day for between one and seven days (e.g. 1, 2, 3, 4, 5, 6, or 7 days) followed by cessation of therapy. Viral load is optionally monitored over time, and after cessation, viral rebound is monitored. Therapy is not resumed unless a significant viral load is again observed, and then therapy for 1-7 days and more preferred, 1, 2 or 3 days, is repeated. This therapy can be continued indefinitely to monitor and maintain the health of the patient.
摘要翻译：用于治疗黄病毒科感染（包括丙型肝炎病毒感染）的剂量组，其包括以约50mg / m 2至约约50mg / m 2的剂量范围施用吉西他滨（或其盐，前药或衍生物，如本文所述） 1300mg / m 2，每天1至7天（例如1,2,3,4,5,6或7天），然后停止治疗。可随时随地监测病毒载量，停止后监测病毒反弹。除非再次观察到显着的病毒载量，否则不会恢复治疗，然后重复1-7天，更优选1,2或3天的治疗。这种治疗可以无限期地持续以监测和维持患者的健康。

65. 发明申请

US20030220245A1 Conjugate addition reactions for the controlled delivery of pharmaceutical active compounds 有权
标题翻译：用于药物活性化合物受控递送的共轭加成反应
公开(公告)号：US20030220245A1
公开(公告)日：2003-11-27
申请号：US10297229
申请日：2003-03-24
发明人： Jeffrey A Hubbell , Donald Elbert , Ronald Schoenmakers
IPC分类号： A61K038/17 , A61K048/00 , A61K038/14 , A61K031/7072 , A61K031/704 , A61K031/4745 , A61K031/56 , A61K031/337
CPC分类号： A61K31/337 , A61K31/4745 , A61K31/56 , A61K31/704 , A61K31/7072 , A61K31/7088 , A61K47/60 , A61K47/62 , A61K47/6903 , A61K48/00 , A61L24/0015 , A61L24/0031 , A61L27/52 , A61L27/54 , A61L2300/222 , A61L2300/416 , A61L2300/43 , A61L2300/602
摘要： The invention features polymeric biomaterials formed by nucleophilic addition reactions to conjugated unsaturated groups. These biomaterials may be used for medical treatments.
摘要翻译：本发明的特征在于通过对共轭不饱和基团的亲核加成反应形成的聚合物生物材料。这些生物材料可用于医疗治疗。

66. 发明申请

US20030211180A1 Herbal composition phy906 and its use in chemotheraphy 有权
标题翻译：草药组成phy906及其在化学疗法中的应用
公开(公告)号：US20030211180A1
公开(公告)日：2003-11-13
申请号：US10220876
申请日：2002-12-30
发明人： Yung-Chi Cheng , Shwu-Huey Liu
IPC分类号： A61K035/78 , A61K031/7072
CPC分类号： A61K36/48 , A61K36/484 , A61K36/539 , A61K36/65 , A61K36/725 , A61K2300/00
摘要： This invention provides herbal compositions useful for increasing the therapeutic index of drugs, including those used in the treatment of disease, especially viral infections and neoplasms of cancer. This invention provides methods useful for improving the quality of life of an individual undergoing chemotherapy. Furthermore, this invention improves the treatment of disease by increasing the therapeutic index of chemotherapy drugs by administering the herbal composition PHY906 to a person undergoing such chemotherapy.
摘要翻译：本发明提供了可用于增加药物治疗指数（包括用于治疗疾病，特别是病毒感染和癌症肿瘤）的药物组合物的草药组合物。本发明提供了有助于改善接受化疗的个体的生活质量的方法。此外，本发明通过将药草组合物PHY906施用于经历这种化疗的人，通过增加化疗药物的治疗指数来改善疾病的治疗。

67. 发明申请

US20030199473A1 Substituted diamino-1,3,5-triazine derivatives 失效
标题翻译：取代的二氨基-1,3,5-三嗪衍生物
公开(公告)号：US20030199473A1
公开(公告)日：2003-10-23
申请号：US10397760
申请日：2003-03-26
申请人： Janssen Pharmaceutica N.V.
发明人： Paul A.J. Janssen , Jan Heeres , Henri E.L. Moereels , Michael Joseph Kukla , Donald W. Ludovici
IPC分类号： A61K031/721 , A61K031/7072 , A61K031/551 , A61K031/66 , A61K031/513 , A61K031/16
CPC分类号： C07D403/06 , C07D251/18 , C07D251/48 , C07D405/06 , C07D405/12 , C07D409/12
摘要： This invention concerns the compounds of formula 1 the pharmaceutically acceptable acid addition salts and the stereochemically isomeric forms thereof, wherein R1 and R2 are each independently selected from hydrogen; hydroxy; amino; optionally substituted C1-6alkyl; C1-6alkyloxy; C1-6alkylcarbonyl; C1-6alkyloxycarbonyl; Ar1; mono- or di(C1-6alkyl)amino; mono- or di(C1-6alkyl)aminocarbonyl; dihydro-2(3H)-furanone; or R1 and R2 taken together may form pyrrolidinyl, piperidinyl, morpholinyl, azido or mono- or di(C1-6alkyl)aminoC1-4alkylidene; R3 is hydrogen, Ar1, C1-6alkylcarbonyl, C1-6alkyl, C1-6alkyloxycarbonyl, C1-6alkyl substituted with C1-6alkyloxycarbonyl; and R4, R5, R6, R7 and R8 are each independently selected from hydrogen, halo, C1-6alkyl, C1-6alkyloxy, cyano, aminocarbonyl, nitro, amino, trihalomethyl or trihalomethyloxy; L is optionally substituted C1-10alkyl; C3-10alkenyl; C3-10alkynyl; C3-7cycloalkyl; Ar1 is optionally substituted phenyl; for the manufacture of a medicine for the treatment of subjects suffering from HIV (Human Immunodeficiency Virus) infection. It further relates to new compounds being a subgroup of the compounds of formula (I), their preparation and compositions comprising them.
摘要翻译：本发明涉及式的化合物，其药学上可接受的酸加成盐及其立体化学异构形式，其中R 1和R 2各自独立地选自氢; 羟基; 氨基; 任选取代的C 1-6烷基; C 1-6烷氧基; C 1-6烷基羰基; C 1-6烷氧基羰基; Ar <1>; 单或二（C 1-6烷基）氨基; 单或二（C 1-6烷基）氨基羰基; 二氢-2（3H） - 呋喃酮; 或R 1和R 2一起可以形成吡咯烷基，哌啶基，吗啉基，叠氮基或单或二（C 1-6烷基）氨基C 1-4亚烷基; R 3是氢，Ar 1，C 1-6烷基羰基，C 1-6烷基，C 1-6烷氧基羰基，被C 1-6烷氧基羰基取代的C 1-6烷基; R 4，R 5，R 6，R 7和R 8各自独立地选自氢，卤素，C 1-6烷基，C 1-6烷氧基，氰基，氨基羰基，硝基，氨基，三卤甲基或三卤代甲氧基; L是任选取代的C 1-10烷基; C3-10烯基; C3-10炔基; C 3-7环烷基; Ar 1是任选取代的苯基; 用于制造用于治疗患有HIV（人类免疫缺陷病毒）感染的受试者的药物。它还涉及作为式（I）化合物的亚组的新化合物，其制备方法和包含它们的组合物。

68. 发明申请

US20030186927A1 Ectocornea extension promoters 有权
标题翻译： Ectocornea延伸启动子
公开(公告)号：US20030186927A1
公开(公告)日：2003-10-02
申请号：US10297233
申请日：2003-05-20
发明人： Katsuhiko Nakata , Masatsugu Nakamura , Tsutomu Fujihara , Hiromi Fujita
IPC分类号： A61K031/7076 , A61K031/7072
CPC分类号： A61K31/00 , A61K31/7072 , A61K31/7076 , A61K31/7084 , Y10S514/912
摘要： Based on research for compounds that can display a corneal epithelial migration promoting effect in ophthalmology, the present invention provides P2Y receptor agonist corneal epithelial migration promoters, such as phosphoric acid compounds having an adenosyl group, uridyl group, xanthosyl group, guanosyl group, or thymidyl group, or their salts, with excellent corneal epithelial migration promoting effects.
摘要翻译：基于可以在眼科中显示角膜上皮迁移促进作用的化合物的研究，本发明提供了P2Y受体激动剂角膜上皮迁移启动子，例如具有腺苷基，磷脂酰基，黄嘌呤基，鸟苷基或胸苷的磷酸化合物组或其盐，具有优异的角膜上皮迁移促进作用。

69. 发明申请

US20030171329A1 Stable compositions comprising tezacitabine 审中-公开
标题翻译：包含tezacitabine的稳定组合物
公开(公告)号：US20030171329A1
公开(公告)日：2003-09-11
申请号：US10365896
申请日：2003-02-12
发明人： Richard E. Jones , Mike T. Li , Andy Trammel , Christine M. Harrison-Bowman , Kimberly R. Shirley
IPC分类号： A61K031/7072
CPC分类号： A61K9/0019 , A61K31/7072 , A61K47/02 , A61K47/18 , A61K47/183
摘要： The present invention relates to tezacitabine ((E)-2null-fluoromethylene-2null-deoxycytidine) formulations which are stable for long periods of time. The present invention further relates to methods of formulating stable tezacitabine formulations.
摘要翻译：本发明涉及长时间稳定的替扎他宾（（E）-2'-氟亚甲基-2'-脱氧胞苷）制剂。本发明还涉及制备稳定的tezacitabine制剂的方法。

70. 发明申请

US20030158128A1 Treatment, composition and method using uracil against side-effects of chemotherapy 审中-公开
标题翻译：使用尿嘧啶治疗化疗副作用的治疗，组合和方法
公开(公告)号：US20030158128A1
公开(公告)日：2003-08-21
申请号：US10364383
申请日：2003-02-12
发明人： John P. Ford
IPC分类号： A61K031/7072 , A61K031/704 , A61K031/513 , A61K031/337
CPC分类号： A61K31/555 , A61K31/00 , A61K31/337 , A61K31/513 , A61K31/704 , A61K31/7072 , A61K2300/00
摘要： A treatment, method and composition is provided for combating tumors by administering to a person suffering from tumors to the body tissue an effective amount of anti-cancer drugs such as 5-fluorouracil or a precursor thereof, followed by application of uracil in a pharmaceutically acceptable carrier to reduce hand-foot syndrome.
摘要翻译：提供了治疗，方法和组合物，用于通过向患有肿瘤的人向身体组织施用有效量的抗癌药物，例如5-氟尿嘧啶或其前体，随后将尿嘧啶施用于药学上可接受的携带者减少手足综合征。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式